Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo

被引:51
作者
Darouiche, RO
Mansouri, MD
机构
[1] Vet Affairs Med Ctr, Infect Dis Sect, Houston, TX 77030 USA
[2] Vet Affairs Med Ctr, Ctr Prosthese Infect, Houston, TX 77030 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
关键词
dalbavancin; vancomycin; Staphylococcus aureus; device colonization;
D O I
10.1016/j.jinf.2004.05.006
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Objectives. Although active against free-floating bacteria, vancomycin displays a poor activity against organisms embedded within the biofilm surrounding implanted devices. Dalbavancin is a novel gtycopeptide antibiotic with strong activity against staphylococci and a long half-life that allows for once-a-week dosing. The objective of this animal study was to examine the ability of dalbavancin and vancomycin to prevent Staphylococcus aureus colonization of devices. Methods. Twelve rabbits were randomized, in three groups of four each, to receive intravenous injections of dalbavancin, vancomycin or normal saline (control). Eight polyurethane catheter segments were subcutaneously implanted in the back of each rabbit, then inoculated with S. aureus. Rabbits were sacrificed a week later and exptanted devices were cultured. Results. The rates of device colonization were comparable in the vancomycin (53%) and control (47%) groups, whereas only 28% of devices in the dalbavancin group became colonized. There was a trend (although not statistically significant) toward a tower rate of device colonization following receipt of dalbavancin vs. vancomycin (P = 0.07) or saline (P = 0.20). Conclusions: The demonstrated efficacy of dalbavancin in this animal study suggest that this novel antibiotic may have an important role in the prevention and treatment of device-related infection. (c) 2004 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:206 / 209
页数:4
相关论文
共 16 条
[1]
Initial quality control evaluations for susceptibility testing of dalbavancin (BI397), an Investigational glycopeptide with potent gram-positive activity [J].
Anderegg, TR ;
Biedenbach, DJ ;
Jones, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (06) :2795-2796
[2]
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic [J].
Candiani, G ;
Abbondi, M ;
Borgonovi, M ;
Romanò, G ;
Parenti, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :179-192
[3]
Bacterial biofilms: A common cause of persistent infections [J].
Costerton, JW ;
Stewart, PS ;
Greenberg, EP .
SCIENCE, 1999, 284 (5418) :1318-1322
[4]
Linezolid compared with eperezolid, vancomycin, and gentamicin in an in vitro model of antimicrobial lock therapy for Staphylococcus epidermidis central venous catheter-related biofilm infections [J].
Curtin, J ;
Cormican, M ;
Fleming, G ;
Keelehan, J ;
Colleran, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3145-3148
[5]
Antimicrobial approaches for preventing infections associated with surgical implants [J].
Darouiche, RO .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (10) :1284-1289
[6]
VANCOMYCIN PENETRATION INTO BIOFILM COVERING INFECTED PROSTHESES AND EFFECT ON BACTERIA [J].
DAROUICHE, RO ;
DHIR, A ;
MILLER, AJ ;
LANDON, GC ;
RAAD, II ;
MUSHER, DM .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 (03) :720-723
[7]
Darouiche RO, 1998, J HEART VALVE DIS, V7, P639
[8]
Device-associated infections: A macroproblem that starts with microadherence [J].
Darouiche, RO .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1567-1572
[9]
Biofilms: Survival mechanisms of clinically relevant microorganisms [J].
Donlan, RM ;
Costerton, JW .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (02) :167-+
[10]
Investigation of the antimicrobial effects of linezolid on bacterial biofilms utilizing an in vitro pharmacokinetic model [J].
Gander, S ;
Hayward, K ;
Finch, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) :301-308